Alpha Teknova logo

Alpha TeknovaNASDAQ: TKNO

Profile

Sector:

Healthcare

Country:

United States

IPO:

25 June 2021

Next earnings report:

11 March 2025

Last dividends:

N/A

Next dividends:

N/A
$317.71 M
-54%vs. 3y high
60%vs. sector
-vs. 3y high
-vs. sector
-33%vs. 3y high
75%vs. sector
-54%vs. 3y high
75%vs. sector

Price

after hours | Sat, 16 Nov 2024 00:34:48 GMT
$5.96-$1.18(-16.53%)

Dividend

No data over the past 3 years
$9.58 M$8.78 M
$9.58 M-$7.57 M

Analysts recommendations

Institutional Ownership

TKNO Latest News

Alpha Teknova, Inc. (TKNO) Q3 2024 Earnings Call Transcript
seekingalpha.com09 November 2024 Sentiment: NEUTRAL

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q3 2024 Earnings Conference Call November 7, 2024 5:30 PM ET Company Participants Jennifer Henry – Senior Vice President-Marketing Stephen Gunstream – President and Chief Executive Officer Matt Lowell – Chief Financial Officer Conference Call Participants Chad Wiatrowski – TD Cowen Lucas Baranowski – KeyBanc Capital Markets Vidyun Bais – BTIG Jacob Johnson – Stephens Matt Larew – William Blair Operator Hello, and welcome to Alpha Teknova Third Quarter 2024 Financial Results. At this time all participants are in a listen-only mode.

Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024
globenewswire.com24 October 2024 Sentiment: POSITIVE

HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market.

What Makes Alpha Teknova (TKNO) a Strong Momentum Stock: Buy Now?
zacks.com22 October 2024 Sentiment: POSITIVE

Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Teknova Reports Second Quarter 2024 Financial Results
globenewswire.com13 August 2024 Sentiment: POSITIVE

Second quarter 2024 total revenue was $9.6 million, up 3% sequentially Raised $15.4 million of equity capital in July 2024 Launched two new offerings: Express-TekSM Production and RUO+ manufacturing grade Company reaffirms 2024 revenue guidance of $35-38 million

Teknova to Report Second Quarter 2024 Financial Results on August 13, 2024
globenewswire.com30 July 2024 Sentiment: POSITIVE

HOLLISTER, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2024, on Tuesday, August 13, 2024, following the close of market.

Teknova Announces Closing of $15.4 Million Private Placement
globenewswire.com12 July 2024 Sentiment: POSITIVE

HOLLISTER, Calif., July 12, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 12,385,883 shares of its common stock at a purchase price of $1.24 per share. The private placement was priced based on the Nasdaq Official Closing Price of Teknova's common stock on July 11, 2024.

Teknova Announces $15.4 Million Private Placement
globenewswire.com12 July 2024 Sentiment: POSITIVE

HOLLISTER, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate 12,385,883 of its shares of common stock in a private placement at a purchase price of $1.24 per share. The private placement was priced based on the Nasdaq Official Closing Price of Teknova's common stock on July 11, 2024.

Teknova Provides Strategic Business Update and Announces Preliminary Second Quarter 2024 Results
globenewswire.com09 July 2024 Sentiment: POSITIVE

Second quarter 2024 total revenue is in the range of $9.4 to $9.6 million Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today provided a business update including preliminary unaudited financial results for the second quarter ended June 30, 2024.

After Plunging -24.59% in 4 Weeks, Here's Why the Trend Might Reverse for Alpha Teknova (TKNO)
zacks.com24 June 2024 Sentiment: POSITIVE

Alpha Teknova (TKNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Alpha Teknova (TKNO) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com06 June 2024 Sentiment: POSITIVE

Alpha Teknova (TKNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What type of business is Alpha Teknova?

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

What sector is Alpha Teknova in?

Alpha Teknova is in the Healthcare sector

What industry is Alpha Teknova in?

Alpha Teknova is in the Drug Manufacturers - Specialty & Generic industry

What country is Alpha Teknova from?

Alpha Teknova is headquartered in United States

When did Alpha Teknova go public?

Alpha Teknova initial public offering (IPO) was on 25 June 2021

What is Alpha Teknova website?

https://www.teknova.com

Is Alpha Teknova in the S&P 500?

No, Alpha Teknova is not included in the S&P 500 index

Is Alpha Teknova in the NASDAQ 100?

No, Alpha Teknova is not included in the NASDAQ 100 index

Is Alpha Teknova in the Dow Jones?

No, Alpha Teknova is not included in the Dow Jones index

When was Alpha Teknova the previous earnings report?

No data

When does Alpha Teknova earnings report?

The next expected earnings date for Alpha Teknova is 11 March 2025